Medline $MDLN Shares Sold by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company decreased its holdings in Medline (NASDAQ:MDLN) by 14.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 98,575 shares of the company’s stock after selling 17,227 shares during the period. The Manufacturers Life Insurance Company’s holdings in Medline were worth $4,387,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also modified their holdings of MDLN. Sound Income Strategies LLC purchased a new position in Medline in the fourth quarter valued at $25,000. Entrust Financial LLC acquired a new position in Medline during the 4th quarter worth $26,000. NBC Securities Inc. purchased a new stake in Medline during the 4th quarter worth about $28,000. Whipplewood Advisors LLC acquired a new stake in Medline in the 1st quarter valued at about $30,000. Finally, Global Retirement Partners LLC purchased a new position in shares of Medline in the 4th quarter valued at about $31,000.

Insider Activity at Medline

In other Medline news, insider Jessi L. Corcoran purchased 5,000 shares of Medline stock in a transaction that occurred on Friday, June 5th. The stock was purchased at an average price of $34.15 per share, for a total transaction of $170,750.00. Following the transaction, the insider directly owned 5,000 shares in the company, valued at $170,750. This trade represents a ? increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Douglas P. Golwas sold 100,000 shares of the stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $36.77, for a total transaction of $3,677,000.00. Following the sale, the insider owned 23,899 shares of the company’s stock, valued at approximately $878,766.23. This represents a 80.71% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.81% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have recently commented on MDLN shares. Royal Bank Of Canada lowered their price objective on Medline from $53.00 to $46.00 and set an “outperform” rating for the company in a research report on Thursday. BNP Paribas Exane decreased their price target on shares of Medline from $49.00 to $40.00 and set a “neutral” rating for the company in a research note on Thursday, May 14th. Sanford C. Bernstein lowered their price target on shares of Medline from $56.00 to $54.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Robert W. Baird set a $42.00 price objective on shares of Medline in a research report on Thursday. Finally, Tigress Financial raised their price objective on shares of Medline from $60.00 to $62.00 and gave the company a “buy” rating in a report on Wednesday, May 13th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $48.50.

More Medline News

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Medline reported second-quarter revenue of $7.7 billion, up 11.6% year over year, while adjusted EBITDA rose 13.4% to $1.06 billion. Adjusted EPS of $0.50 exceeded the $0.32 analyst consensus. Medline Reports Second Quarter and First Six Months 2026 Results
• Positive Sentiment: Management raised its 2026 organic-sales growth outlook to 9%-10% from 8.5%-9.5%, citing strong demand, new customer wins and existing-customer growth. Operating cash flow and free cash flow also improved substantially in the first half.
• Positive Sentiment: BTIG maintained a Buy rating and $55 price target, while Truist and Stifel retained Buy ratings even after lowering their targets to $47 and $45, respectively. These targets imply analysts still see meaningful upside if Medline executes on its growth plans. BTIG Medline Rating
• Neutral Sentiment: Medline recorded $243 million of net IEEPA tariff-refund benefits in the quarter, partially offset by $89 million in customer repayments. Investors may view this as a temporary benefit rather than a recurring improvement in earnings.
• Negative Sentiment: The company lowered full-year adjusted EBITDA guidance to $3.3-$3.4 billion from $3.5-$3.6 billion. Management cited inflation, higher operating investments, quality-remediation costs, retail-channel weakness and geopolitical pressures.
• Negative Sentiment: Second-quarter net income fell 58.3% to $139 million, and diluted GAAP EPS was only $0.07. A $336 million loss related to the Tracy, California distribution-center fire, along with higher expenses and costs, sharply reduced reported profitability.
• Negative Sentiment: Securities-law firms announced investigations following an FDA warning letter that reportedly identified significant violations. Although the investigations are preliminary, potential regulatory action, litigation costs and operational disruption add to investor uncertainty. Medline Investigation Alert

Medline Stock Down 5.9%

MDLN opened at $34.51 on Friday. Medline has a one year low of $32.81 and a one year high of $50.88. The company has a debt-to-equity ratio of 0.65, a quick ratio of 2.51 and a current ratio of 4.41. The stock has a market capitalization of $45.34 billion and a P/E ratio of 107.84. The business’s 50-day simple moving average is $38.24 and its 200-day simple moving average is $41.77.

Medline (NASDAQ:MDLN) last announced its earnings results on Wednesday, August 5th. The company reported $0.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.32 by $0.18. The firm had revenue of $7.68 billion during the quarter. Analysts anticipate that Medline will post 1.49 EPS for the current year.

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply?chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.